Medivation Inc (MDVN)

MDVN (NASDAQ:Drugs) EQUITY
$60.63
pos +0.00
+0.00%
Today's Range: 59.58 - 60.95 | MDVN Avg Daily Volume: 3,853,700
Last Update: 05/27/16 - 4:00 PM EDT
Volume: 0
YTD Performance: 25.36%
Open: $0.00
Previous Close: $60.31
52 Week Range: $26.41 - $66.40
Oustanding Shares: 164,624,777
Market Cap: 9,928,520,301
6-Month Chart
TheStreet Ratings Grade for MDVN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 11 9 9
Moderate Buy 0 0 0 0
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.57 1.53 1.62 1.62
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 39.18
Price Earnings Comparisons:
MDVN Sector Avg. S&P 500
39.18 40.20 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
70.37% -7.58% 148.06%
GROWTH 12 Mo 3 Yr CAGR
Revenue 32.80 4.20 0.72
Net Income -11.50 -6.90 0.00
EPS -9.80 -6.50 0.00
Earnings for MDVN:
EBITDA 0.41B
Revenue 0.94B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.24 $0.32 $1.06 $2.48
Number of Analysts 1 1 1 1
High Estimate $0.24 $0.32 $1.06 $2.48
Low Estimate $0.24 $0.32 $1.06 $2.48
Prior Year $0.23 $0.27 $0.68 $1.06
Growth Rate (Year over Year) 2.13% 18.52% 55.88% 133.96%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bret Jensen

 | May 23, 2016 | 11:00 AM EDT

FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.

By

Bret Jensen

 | May 17, 2016 | 10:00 AM EDT

It is hard to see much growth in the market overall, until earnings growth returns.

bullishMedivation upgraded at Citi

May 9, 2016 | 7:57 AM EDT

MDVN was upgraded to Buy, Citigroup said. $73 price target. Xtandi also now appears to be effective against breast cancer.

By

Jim Cramer

 | May 4, 2016 | 3:14 PM EDT

Checking the gauges for underperformance, none of them look good.

bullishMedivation upgraded at Canaccord

Apr 19, 2016 | 7:03 AM EDT

MDVN was upgraded from Hold to Buy, Canaccord Genuity said. $70 price target. Breast and Ovarian cancer treatments can drive growth. 

By

Bret Jensen

 | Apr 14, 2016 | 11:00 AM EDT

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.

By

James "Rev Shark" DePorre

 | Apr 6, 2016 | 10:39 AM EDT

This sort of action is needed periodically.

By

James Passeri

 | Mar 31, 2016 | 8:10 AM EDT

Medivation is surging as Wall Street scouts the Big Pharma front for discounted M&A opportunities.

bearishMedivation downgraded at Canaccord

Jan 27, 2016 | 7:15 AM EST

MDVN was downgraded to Hold, Canaccord Genuity said. $45 price target. Xtandi growth is slowing. 

By

Jim Cramer

 | Jun 5, 2015 | 1:23 PM EDT

With hacking and cyber security making headlines, Jim Cramer recommended a few cyber security stocks for investors, including Palo Alto Networks (PANW), Fortinet (FTNT), FireEye (FEYE), and Cyberark Software (CYBR).

Nice finish today for CVX. The stock has been steadily improving after holding key su...
TMO agreed to purchase FEI Company for S4.2 billion dollars this morning. The company ran ...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.